New Treatment For Psoriasis: FDA Approves Taltz
Adults with moderate-to-severe plaque psoriasis have a new treatment option. The FDA has approved an additional systemic drug, Taltz (the brand name for ixekizumab), to help relieve skin irritation and discomfort from plaque psoriasis. Psoriasis affects approximately 7.5 million Americans, approximately 20% with moderate-to-severe symptoms. Taltz, manufactured by Eli Lilly and Company, is a monoclonal antibody that binds to interleukin (IL)-17A, which is partially responsible for the inflammation in psoriasis, and thus inhibits this inflammatory response.
Three randomized, controlled studies established the safety and efficacy of the new drug. The results showed that Taltz, which is delivered by injection, achieved a greater clinical response than the placebo, and up to 41% of those treated with Taltz were able to achieve clear skin. The European Medicines Agency’s Committee for Medicinal Products has also approved Taltz. Though Taltz was quite effective at achieving complete clearance of skin plaques, Taltz may increase the risk of certain infections such as upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections.
Byline: Martha L. Sikes, MS, RPh, PA-C
Posted: April 25, 2016